CD8A and diffuse large B-cell lymphoma: This could be a reason for the failure of modern DLBCL therapies such as checkpoint inhibitors, CAR-T, bispecific antibodies, and nanobodies therapies, based on the CD8+ T cell presence in the tumour niche.